NASDAQ:TLSI TriSalus Life Sciences (TLSI) Stock Price, News & Analysis $4.38 +0.22 (+5.24%) As of 01:49 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About TriSalus Life Sciences Stock (NASDAQ:TLSI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get TriSalus Life Sciences alerts:Sign Up Key Stats Today's Range$4.16▼$4.5750-Day Range$2.52▼$4.6552-Week Range$2.20▼$7.95Volume230,837 shsAverage Volume294,486 shsMarket Capitalization$268.90 millionP/E RatioN/ADividend YieldN/APrice Target$7.50Consensus RatingHold Company Overview TriSalus Life Sciences, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs. The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents. TriSalus collaborates with academic medical centers and cancer research institutions across the United States to advance its candidates through regulatory and clinical milestones. By integrating novel delivery technologies with proven oncology drugs, TriSalus seeks to optimize therapeutic outcomes in both recurrent and metastatic disease settings. Headquartered in Houston, Texas, TriSalus operates research and development facilities in strategic North American life-science hubs. Its leadership team brings together seasoned professionals with backgrounds in pharmaceutical development, medical devices, and oncology therapeutics. As the company progresses through clinical validation, it plans to expand its technology platform into additional solid tumor indications, aiming to provide safer, more effective treatment options for cancer patients worldwide.AI Generated. May Contain Errors. Read More TriSalus Life Sciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks59th Percentile Overall ScoreTLSI MarketRank™: TriSalus Life Sciences scored higher than 59% of companies evaluated by MarketBeat, and ranked 325th out of 848 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingHold Consensus RatingTriSalus Life Sciences has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialTriSalus Life Sciences has a consensus price target of $7.50, representing about 75.8% upside from its current price of $4.27.Amount of Analyst CoverageTriSalus Life Sciences has only been the subject of 2 research reports in the past 90 days.Read more about TriSalus Life Sciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for TriSalus Life Sciences are expected to grow in the coming year, from ($0.45) to ($0.25) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of TriSalus Life Sciences is -3.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of TriSalus Life Sciences is -3.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about TriSalus Life Sciences' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted4.09% of the float of TriSalus Life Sciences has been sold short.Short Interest Ratio / Days to CoverTriSalus Life Sciences has a short interest ratio ("days to cover") of 4.91.Change versus previous monthShort interest in TriSalus Life Sciences has recently increased by 24.72%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTriSalus Life Sciences does not currently pay a dividend.Dividend GrowthTriSalus Life Sciences does not have a long track record of dividend growth. News and Social Media0.6 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 3 news articles for TriSalus Life Sciences this week, compared to 2 articles on an average week.MarketBeat Follows1 people have added TriSalus Life Sciences to their MarketBeat watchlist in the last 30 days. Company Ownership4.2 / 5Insider TradingAcquiring Shares Cluster Insider Buying4 insiders have purchased shares of TriSalus Life Sciences in the last three months. Multiple insiders buying is a strong bullish signal.Net Insider BuyingOver the last three months, insiders have purchased a net $1,804,176.00 in company stock, which represents 0.6884% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, TriSalus Life Sciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,804,176.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders16.30% of the stock of TriSalus Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions2.58% of the stock of TriSalus Life Sciences is held by institutions.Read more about TriSalus Life Sciences' insider trading history. Receive TLSI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TriSalus Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TLSI Stock News HeadlinesINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TriSalus Life Sciences Inc. - TLSI3 hours ago | prnewswire.comCritical Review: TriSalus Life Sciences (NASDAQ:TLSI) vs. Valneva (NASDAQ:VALN)June 25 at 4:59 AM | americanbankingnews.comFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the biggest story of his 26-year career - an economic shift not seen since 1776. From the government taking stakes in Intel, Lithium Americas, and MP Materials, to sweeping political changes reshaping the economy, Stansberry argues a rare 'New 1776 Moment' is already underway. One Nobel Prize winner calls it a dividing line for all of society. His presentation covers the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift.June 25 at 1:00 AM | Porter & Company (Ad)INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TriSalus Life Sciences Inc. - TLSIJune 23 at 5:45 PM | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TriSalus Life Sciences Inc. - TLSIJune 18, 2026 | prnewswire.comTLSI Investors Have Opportunity to Join TriSalus Life Sciences, Inc. Fraud Investigation with the Schall Law FirmJune 17, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TriSalus Life Sciences Inc. - TLSIJune 16, 2026 | globenewswire.comTLSI Investors Have Opportunity to Join TriSalus Life Sciences, Inc. Fraud Investigation with the Schall Law FirmJune 11, 2026 | prnewswire.comSee More Headlines TLSI Stock Analysis - Frequently Asked Questions How have TLSI shares performed this year? TriSalus Life Sciences' stock was trading at $6.98 on January 1st, 2026. Since then, TLSI shares have decreased by 38.9% and is now trading at $4.2670. How were TriSalus Life Sciences' earnings last quarter? TriSalus Life Sciences, Inc. (NASDAQ:TLSI) announced its quarterly earnings data on Thursday, March, 5th. The company reported ($0.12) earnings per share for the quarter, topping analysts' consensus estimates of ($0.13) by $0.01. The company had revenue of $13.21 million for the quarter, compared to analysts' expectations of $13.20 million. Read the conference call transcript. Who are TriSalus Life Sciences' major shareholders? TriSalus Life Sciences' top institutional shareholders include First Light Asset Management LLC (8.26%), Wasatch Advisors LP (2.35%), Empire Financial Management Company LLC (0.49%) and Perkins Capital Management Inc. (0.38%). Insiders that own company stock include Equity Ab Frankenius, Michael P Stansky, Mary T Szela, George Kelly Martin, Sean Murphy, Bryan F Cox, Mats Wahlstrom, Richard Marshak, Jodi Devlin, Gary B Gordon and James Emmett Young. View institutional ownership trends. How do I buy shares of TriSalus Life Sciences? Shares of TLSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of TriSalus Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that TriSalus Life Sciences investors own include AutoZone (AZO), Intel (INTC), Meta Platforms (META), Merck & Co., Inc. (MRK), TJX Companies (TJX), Abacus Health Products (ABAHF) and Airbnb (ABNB). Company Calendar Last Earnings3/05/2026Today6/25/2026Next Earnings (Estimated)8/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1w+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 For the last 10 days, TLSI's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED PRODUCTS Sub-IndustryMedical Equipment Current SymbolNASDAQ:TLSI Previous SymbolNASDAQ:TLSI CIK1826667 Webtrisaluslifesci.com Phone888-321-5212FaxN/AEmployees106Year Founded2009Price Target and Rating Average Price Target for TriSalus Life Sciences$7.50 High Price Target$8.00 Low Price Target$7.00 Potential Upside/Downside+71.3%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($1.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$39.23 million Net Margins-60.85% Pretax Margin-60.84% Return on EquityN/A Return on Assets-69.91% Debt Debt-to-Equity Ratio2.58 Current Ratio5.78 Quick Ratio5.46 Sales & Book Value Annual Sales$45.15 million Price / Sales5.96 Cash FlowN/A Price / Cash FlowN/A Book Value($0.68) per share Price / Book-6.44Miscellaneous Outstanding Shares61,420,000Free Float51,406,000Market Cap$268.90 million OptionableNot Optionable Beta0.48 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:TLSI) was last updated on 6/25/2026 by MarketBeat.com Staff. From Our PartnersThe 1934 playbookIn 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...American Alternative | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredSpaceX is offering you shares. Don't take them.SpaceX is reserving 30% of its IPO shares for retail investors through Robinhood, Fidelity, and Schwab. At a $...Behind the Markets | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, c...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TriSalus Life Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TriSalus Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
